Study published in Clinical Cancer Research cites important progress towards new treatments for cancer using PharmaJet Tropis
Invectys published the results of their Phase I clinical trial testing their immune-therapeutic DNA cancer vaccine, INVAC-1, using the PharmaJet needle-free injection system (Teixeira et al, 2019). The publication cites that “administration with the PharmaJet Tropis is immunogenic and able to elicit hTERT specific CD4 and CD8 immune responses in patients. Details
Study published in Viruses shows superior response with PharmaJet Tropis over electroporation
Bernelin-Cottet et al published a study that demonstrates the delivery of a DNA-based swine influenza vaccine with the PharmaJet Tropis Needle-free Jet Injector resulted in an increased cellular uptake as compared with administration via needle and syringe followed by electroporation. Importantly, administration by Tropis resulted in a non-inferior immune response, a more efficient cell uptake, and an equal potency to elicit an anti-Neuraminidase IgG response. Details
PharmaJet receives Frost & Sullivan Best Practices Award
Immunization coverage is critical to eradicating potentially deadly diseases while reducing the burden of disease. Safe, cost-effective, and patient-friendly injectable drug delivery systems play a crucial role in the success of global vaccination programs. PharmaJet leverages innovative jet injection technology to offer a needle-free, accurate, and more comfortable method of vaccine delivery. With unparalleled ease-of-use… Details
Needle-free Injection – Eradicating Diseases to Improve Global Health
Needle-free Injection technology has evolved significantly over the last 50 years and is now accepted in many routine immunization settings as a safe and effective vaccine delivery method. Disposable syringe jet injectors are now being used for the delivery of vaccines to eradicate polio, MMR, and influenza, and are showing promising results in vaccine clinical… Details
Clinical Study published in The Lancet shows significantly higher immune response with Needle-free injection
The Lancet recently published a study that demonstrates that the delivery of a Zika virus vaccine with the PharmaJet Stratis Needle-free Jet injector resulted in a higher immune response as compared with administration via needle and syringe. Details
Study published in Heliyon Journal shows superiority of needle-free injection over needle and syringe for poliovirus vaccine fIPV campaigns
Administration of intradermal fractional dose of inactivated poliovirus vaccine (fIPV) has proven to be safe and immunogenic; however, intradermal injection using needle and syringe is technically difficult and requires trained personnel. Details
Clinical study published in Vaccine cites superiority of two fractional doses administered intradermally to one full intramuscular dose. Expands use of PharmaJet Tropis Needle-free Injector
The polio eradication endgame strategic plan calls for the sequential removal of Sabin poliovirus serotypes from the trivalent oral poliovirus vaccine (tOPV), starting with type 2, and the introduction of ≥1 dose of inactivated poliovirus vaccine (IPV), to maintain an immunity base against poliovirus type 2. Details
ONdrug DELIVERY publishes PharmaJet Study that links Needle-free Injection to Increasing Workplace Flu Shot Compliance
ONdrugDELIVERY publishes PharmaJet Study Offering needle-free technology in a workplace influenza immunization program has the potential to help address an unmet need for increasing workplace health immunization rates. Details
Clinical Study published in Vaccine supports reduced dose vaccination with the PharmaJet Tropis Needle-free Injection System
A randomized controlled trial was conducted in Cuba to determine immune responses after one fractional dose (0.1mL or 1/5 the dose size) of inactivated poliovirus vaccine using the PharmaJet Tropis jet Injector, as compared to a full dose (0.5mL) with traditional needle and syringe intradermal technique. DetailsIMPORTANT SAFETY INFORMATION FOR CONSUMERS
What is Afluria®, Influenza Vaccine?
Afluria is an inactivated (virus is not alive) influenza vaccine used for immunization against influenza disease caused by influenza virus subtypes A and B present in the vaccine.